Lates News

Every AI Express, Guojin Securities released a research report on March 31, giving Rongchang Bioscience (688331.SH) a "buy" rating. The main reasons for the rating include: 1) Rapid revenue growth and improved operational efficiency; 2) The successful promotion of the flagship product RC148, with rapid progress domestically and internationally; 3) Attention on expanding new indications for mature products in 2026, with expectations of a further acceleration in commercialization. (Daily Economic News)